Helen Boyd

2.0k citations

43 papers · 1.5k indexed · h-index 20

Co-authors: David G. Tew Colin H. Macphee Kitty Moores Deirdre M. B. Hickey Colin A. Leach Robert J. Ife Kevin J. Milliner Keith E. Suckling
Topics: Protein Kinase Regulation and GTPase Signaling (7 papers)Ubiquitin and proteasome pathways (6 papers)Protein Degradation and Inhibitors (6 papers)
Cited by: Cancer Research Biochemistry Molecular Medicine
Journals: Journal of Biological Chemistry Biochemistry Biochemical Journal
Partner nations: United Kingdom United States Sweden

In The Last Decade

Helen Boyd

41 papers receiving 1.5k citations

Peers

Countries citing papers authored by Helen Boyd

Since Specialization

Citations

This map shows the geographic impact of Helen Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Boyd more than expected).

Fields of papers citing papers by Helen Boyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Boyd. The network helps show where Helen Boyd may publish in the future.

Co-authorship network of co-authors of Helen Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Boyd. A scholar is included among the top collaborators of Helen Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Boyd. Helen Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural analysis of the LDL receptor–interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site 2020 ·Journal of Biological Chemistry ·(unknown),Athanassios Adamopoulos,Patrik Johansson,Paul Wan,(unknown),Hongwei Guo,Helen Boyd,Noam Zelcer,Titia K. Sixma	10
2	Adoption of a Turn Conformation Drives the Binding Affinity of p53 C-Terminal Domain Peptides to 14-3-3σ 2019 ·ACS Chemical Biology ·(unknown),(unknown),Kenny Bravo‐Rodriguez,Anders Gunnarsson,Yasser B. Ruiz‐Blanco,Michael Ehrmann,Hongming Chen,Isabelle Landrieu,Elsa Sánchez‐García,Helen Boyd,Christian Ottmann,Richard G. Doveston	11
3	A Comparative Study of Fluorescence Assays in Screening for BRD4 2018 ·Assay and Drug Development Technologies ·(unknown),Helen Boyd,Ian L. Dale,Göran Dahl,(unknown),Wayne P. Bowen,(unknown),Colin J. Dunsmore,Graham Cotton,Helena Lindmark	3
4	Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort 2015 ·Value in Health ·Sameer Kotak,Jack Mardekian,N. Horowicz-Mehler,(unknown),Andrew Burgess,Joseph Kim,E. Gemmen,Helen Boyd,Andrew Koenig	7
5	Assessing HTS Performance Using BioAssay Ontology: Screening and Analysis of a Bacterial Phospho-N-Acetylmuramoyl-Pentapeptide Translocase Campaign 2014 ·Assay and Drug Development Technologies ·(unknown),(unknown),Eva Hansson,Helen Boyd	5
6	Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. 2014 ·PubMed ·Paul Emery,Gaia Gallo,Helen Boyd,Christopher Ll. Morgan,Craig J. Currie,C Poole,Henk Nab	19
7	Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data 2013 ·Lara D. Veeken ·Christopher Ll. Morgan,Paul Emery,Duncan Porter,Alan Reynolds,Andrew W. Young,Helen Boyd,Chris D. Poole,Craig J. Currie	53
8	Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers 2013 ·International Journal of Rheumatology ·(unknown),Anadi Mahajan,Dean Spurden,Helen Boyd,Duncan Porter	29
9	Development on Aegir Reeling Pipeline Analyses by Test Validation 2013 ·(unknown),Helen Boyd,(unknown),(unknown),(unknown)	2
10	Early evaluation of compound QT prolongation effects: A predictive 384-well fluorescence polarization binding assay for measuring hERG blockade 2006 ·Journal of Pharmacological and Toxicological Methods ·(unknown),David H. Singleton,(unknown),(unknown),(unknown),David A. Price,James G. Boyd,Helen Boyd,Jill Steidl‐Nichols,Christine A. Williams	33
11	NanoStore: A Concept for Logistical Improvements of Compound Handling in High-Throughput Screening 2005 ·SLAS DISCOVERY ·Neil Benson,Helen Boyd,Jeremy R. Everett,(unknown),Philip Gribbon,(unknown),Karsten Henco,(unknown),William H. Martin,(unknown),Robert E. Sharp,Robin W. Spencer,(unknown),(unknown),Dirk Winkler	13
12	Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones 2002 ·Bioorganic & Medicinal Chemistry Letters ·Helen Boyd,(unknown),Deirdre M. B. Hickey,Robert J. Ife,Colin A. Leach,Colin H. Macphee,Kevin J. Milliner,Ivan L. Pinto,(unknown),Stephen A. Smith,Ian Stansfield,Steven J. Stanway,Colin J. Theobald,(unknown)	25
13	Development of a 1-μl Scale Assay for Mitogen-Activated Kinase Kinase 7 Using 2-D Fluorescence Intensity Distribution Analysis Anisotropy 2002 ·SLAS DISCOVERY ·P.A. Wright,Helen Boyd,Richard C. Bethell,Michael Busch,Philip Gribbon,(unknown),(unknown),(unknown),Dirk Winkler,Neil Benson	12
14	The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2 2001 ·Bioorganic & Medicinal Chemistry Letters ·Helen Boyd,Beverley Hammond,(unknown),Robert J. Ife,Colin A. Leach,Vahn A. Lewis,Colin H. Macphee,Kevin J. Milliner,Ivan L. Pinto,Stephen A. Smith,Ian Stansfield,Colin J. Theobald,(unknown)	8
15	1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A 2 2001 ·Bioorganic & Medicinal Chemistry Letters ·Jackie C. Bloomer,Helen Boyd,(unknown),Robert J. Ife,Colin A. Leach,Colin H. Macphee,Kevin J. Milliner,Ivan L. Pinto,(unknown),Stephen A. Smith,Ian Stansfield,Steven J. Stanway,Maxine Taylor,Colin J. Theobald,(unknown)	13
16	N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2 2000 ·Bioorganic & Medicinal Chemistry Letters ·Helen Boyd,(unknown),(unknown),Deirdre M. B. Hickey,Robert J. Ife,Colin A. Leach,Colin H. Macphee,Kevin J. Milliner,Kitty Moores,Ivan L. Pinto,Rod A. Porter,(unknown),Stephen A. Smith,Ian Stansfield,David G. Tew,Colin J. Theobald,(unknown)	24
17	natural product derived inhibitors of lipoprotein associated phospholipase a2, synthesis and activity of analogues of sb-253514 2000 ·Bioorganic & Medicinal Chemistry Letters ·Ivan L. Pinto,Helen Boyd,Deirdre M. B. Hickey	25
18	2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2 2000 ·Bioorganic & Medicinal Chemistry Letters ·Helen Boyd,(unknown),(unknown),Robert J. Ife,(unknown),Colin A. Leach,Colin H. Macphee,Kevin J. Milliner,(unknown),Brian P. Slingsby,Stephen A. Smith,Ian Stansfield,David G. Tew,Colin J. Theobald	17
19	Anti-atherosclerotic effect of SB-244323, a lipoprotein associated phospholipase A2 inhibitor, in WHHL rabbits 2000 ·Atherosclerosis ·G. Martin Benson,David C. Grimsditch,(unknown),Kitty Moores,Helen Boyd,David G. Tew,Deirdre M. B. Hickey,Robert J. Ife,Keith E. Suckling,Colin H. Macphee	12
20	Mechanism of Inhibition of LDL Phospholipase A₂ by Monocyclic-β-lactams. Burst Kinetics and the Effect of Stereochemistry 1998 ·Biochemistry ·David G. Tew,Helen Boyd,Stephen Ashman,Colin J. Theobald,Colin A. Leach	37

About Helen Boyd

Helen Boyd is a scholar working on Hematology, Biochemistry and Metals and Alloys, having authored 43 papers that have together received 1.5k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (7 papers), Ubiquitin and proteasome pathways (6 papers) and Protein Degradation and Inhibitors (6 papers). The work is most often cited by research in Cancer Research (283 citations), Biochemistry (73 citations) and Molecular Medicine (56 citations). Helen Boyd has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include David G. Tew, Colin H. Macphee, Kitty Moores, Deirdre M. B. Hickey, Colin A. Leach, Robert J. Ife, Kevin J. Milliner, Keith E. Suckling, Rebecca A. Patterson and David S. Leake. Their work appears in journals such as Journal of Biological Chemistry, Biochemistry and Biochemical Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact